{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:29:19Z","timestamp":1791404959970,"version":"4.3.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . Local tolerability and treatment satisfaction were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>26-week randomized, controlled phase 3 safety and tolerability trial in six countries (Nbib2382939).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Male or female patients aged 18\u201379 years with adult GH deficiency (AGHD), treated with once-daily GH for \u22656 months, were randomized to once-weekly somapacitan (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200961) or once-daily Norditropin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931) administered subcutaneously by pen. Both treatments were dose titrated for 8 weeks to achieve insulin-like growth factor I (IGF-I) standard deviation score (SDS) levels within the normal range, and then administered at a fixed dose. Outcome measures were adverse events (AEs), including injection site reactions; occurrence of anti-somapacitan\/anti-GH antibodies and change in treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean IGF-I SDS remained between 0 and 2 SDS throughout the trial in both groups. AEs were mostly mild or moderate and transient in nature. The most common AEs were nasopharyngitis, headache and fatigue in both groups. More than 1500 somapacitan injections were administered and no clinically significant injection site reactions were reported. No anti-somapacitan or anti-GH antibodies were detected. The TSQM-9 score for convenience increased significantly more with somapacitan vs Norditropin (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0171).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this 26-week trial in patients with AGHD, somapacitan was well tolerated and no safety issues were identified. Once-weekly somapacitan was reported to be more convenient than once-daily Norditropin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eje-17-1073","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T20:25:34Z","timestamp":1520022334000},"page":"491-499","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":72,"title":["Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial"],"prefix":"10.1093","volume":"178","author":[{"given":"Gudmundur","family":"Johannsson","sequence":"first","affiliation":[{"name":"1University of G\u00f6teborg and Sahlgrenska University Hospital, G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[{"name":"2Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Holme","family":"H\u00e5konsson","sequence":"additional","affiliation":[{"name":"3Global Development, Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Biering","sequence":"additional","affiliation":[{"name":"4MediCover Berlin-Mitte MVZ, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[{"name":"5Reference Centre for Rare Diseases of Thyroid and Hormone Receptors, Member of EndoERN Network, CHU Angers Centre Hospitalier Universitaire, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"6Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Toogood","sequence":"additional","affiliation":[{"name":"7Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H\u00f8jby","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"3Global Development, Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"_","family":"_","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"_","family":"_","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Biering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Karges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Sandahl","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels Krarup","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine","family":"Borresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Kerlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"H\u00f6ybye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Marie","family":"Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Higham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Toogood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Brooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"ref141","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem.83.2.4594","article-title":"Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee","volume":"83","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref211","first-page":"715","article-title":"A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency","volume":"15","year":"2002","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13030","article-title":"Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood?","volume":"84","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","year":"2009","journal-title":"Health and Quality of Life Outcomes"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial","volume":"87","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"ref191","first-page":"1","article-title":"perspective on the development of long - acting growth hormone preparations https org","journal-title":"Growth Hormone Research Society European Journal of Endocrinology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","year":"2008","journal-title":"Endocrine Practice"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ghir.2011.01.001","article-title":"Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency","volume":"21","year":"2011","journal-title":"Growth Hormone and IGF Research"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"201499","DOI":"10.1210\/jc.2014-1702","article-title":"RasmussenMHBraendholt OlsenMWAlifrangisLKlimSSuntumM reversible albumin - binding growth hormone derivative is well - tolerated and possesses a potential once - weekly treatment profile of and https org","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beem.2014.09.006","article-title":"Growth hormone replacement in adults \u2013 current standards and new perspectives","volume":"29","year":"2015","journal-title":"Best Practice and Research Clinical Endocrinology and Metabolism"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007995.2015.1117433","article-title":"A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes","volume":"32","year":"2016","journal-title":"Current Medical Research and Opinion"},{"key":"ref21","first-page":"64","article-title":"Adult growth hormone deficiency \u2013 benefits, side effects, and risks of growth hormone replacement","volume":"4","year":"2013","journal-title":"Frontiers in Endocrinology"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13256","article-title":"The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet(R) International Outcome Study","volume":"86","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","article-title":"Patients with osteoporosis prefer once weekly to once daily dosing with alendronate","volume":"48","year":"2004","journal-title":"Maturitas"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","year":"2004","journal-title":"Health and Quality of Life Outcomes"},{"key":"ref131","first-page":"23","article-title":"predictability and protraction in a basal insulin analogue : the pharmacology of insulin detemir of Obesity and Related Metabolic Disorders Supplement https org","author":"KurtzhalsP","journal-title":"Engineering International Journal"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/1756-0500-7-813","article-title":"Impact of adult growth hormone deficiency on daily functioning and well-being","volume":"7","year":"2014","journal-title":"BMC Research Notes"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-09-0422","article-title":"Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH","volume":"161","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","year":"2009","journal-title":"Endocrine Reviews"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1210\/jc.2015-3279","article-title":"A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ghir.2015.06.006","article-title":"Reviewing the safety of GH replacement therapy in adults","volume":"25","year":"2015","journal-title":"Growth Hormone and IGF Research"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/178\/5\/EJE-17-1073.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-17-1073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:11:40Z","timestamp":1676373100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/178\/5\/491\/6655376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":27,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/eje-17-1073","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}